Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

172 ta ish

Ish: Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms

  1. Tumor Cell-Targeting and Tumor Microenvironment–Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic/Photothermal/Chemodynamic Treatment of Cervical Cancer

    Ying Wang, Yiyan Xu, Jiayu Song +8

    MaqolaOchiq kirish202411 iqtibos
    ABI

  2. Disorders of cancer metabolism: The therapeutic potential of cannabinoids

    Dingya Sun, Xin Li, Shengdan Nie +2

    Sharh maqolaOchiq kirish20229 iqtibos
    ABI

  3. <scp>CHB</scp> patients with <scp>rtA181T</scp>‐mutated <scp>HBV</scp> infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes

    Qiqi Ning, Tongwang Yang, Xianghua Guo +8

    MaqolaOchiq kirish20239 iqtibos
    ABI

  4. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Maqola20238 iqtibos
    ABI

  5. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Sharh maqolaOchiq kirish20236 iqtibos
    ABI

  6. Exploring treatment options in cancer: tumor treatment strategies

    Beilei Liu, Hongyu Zhou, Licheng Tan +2

    Sharh maqolaOchiq kirish20245 iqtibos
    ABI

  7. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder

    Yutao Lou, Mengting Cheng, Qin Cao +7

    Maqola20235 iqtibos
    ABI

  8. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy

    Zhibin Wang, Xiu Zhang, Chao Fang +4

    Sharh maqola20245 iqtibos
    ABI

  9. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1)

    Fei Li, Jiaqi Tian, Lin Zhang +2

    Sharh maqola20244 iqtibos
    ABI

  10. Alantolactone: structural enhancements and therapeutic insights for cancer and inflammation

    Muzaffar Kayumov, Fotima A. Sobirova, Okhunjon Khasanov +3

    Sharh maqolaSesquiterpenes and Asteraceae StudiesNatural Product Research20253 iqtibos
    ABI

  11. Innovation networks in the advanced medical equipment industry: supporting regional digital health systems from a local–national perspective

    Feng Hu, Huijie Yang, Liping Qiu +6

    MaqolaOchiq kirish20253 iqtibos
    ABI

  12. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)

    Chang Hoon Ji, Min Ju Lee, Hee Yeon Kim +5

    Boshqa20223 iqtibos
    ABI

  13. Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs

    Madhukiran R. Dhondale, Pradip Thakor, Amritha G. Nambiar +4

    Sharh maqolaOchiq kirish20232 iqtibos
    ABI

  14. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

    Jill Hallin, Lars D. Engstrom, Lauren Hargis +31

    MaqolaOchiq kirish20192 iqtibos
    ABI

  15. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

    Longchuan Bai, Haibin Zhou, Renqi Xu +15

    Maqola20192 iqtibos
    ABI

  16. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

    Ian Churcher

    Sharh maqola20172 iqtibos
    ABI

  17. AUTACs: Cargo-Specific Degraders Using Selective Autophagy

    Daiki Takahashi, Jun Moriyama, Tomoe Y. Nakamura +6

    Maqola20192 iqtibos
    ABI

  18. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

    Xin Lin, Hua Xiang, Guoshun Luo

    Sharh maqola20202 iqtibos
    ABI

  19. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

    Adam D. Cotton, Duy Nguyen, Josef A. Gramespacher +2

    Maqola20212 iqtibos
    ABI

  20. Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

    Heng Zhang, Yu Han, Yuanfan Yang +7

    Maqola20212 iqtibos
    ABI

  21. PROTAC targeted protein degraders: the past is prologue

    Miklós Békés, David R. Langley, Craig M. Crews

    Sharh maqola20222 iqtibos
    ABI

  22. Proteolysis-targeting chimeras (PROTACs) in cancer therapy

    Xinyi Li, Wenchen Pu, Qingquan Zheng +3

    Maqola20222 iqtibos
    ABI

  23. Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases

    Fengzhi Li, Ieman Aljahdali, Xiang Ling

    Sharh maqola20222 iqtibos
    ABI

  24. Targeted Protein Degradation via Lysosomes

    Rishi R. Paudel, Dong Lu, Sandipan Chowdhury +2

    Sharh maqola20222 iqtibos
    ABI

  25. Targeted Protein Degradation: Clinical Advances in the Field of Oncology

    Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova +1

    Sharh maqola20222 iqtibos
    ABI